Asset Details
Do you wish to reserve the book?
Recurrent pituitary apoplexy: experience from a national registry and review of the literature
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Recurrent pituitary apoplexy: experience from a national registry and review of the literature
Do you wish to request the book?
Recurrent pituitary apoplexy: experience from a national registry and review of the literature
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Recurrent pituitary apoplexy: experience from a national registry and review of the literature
2026
Overview
Recurrent pituitary apoplexy: a rare event with favorable outcomes Pituitary apoplexy is a sudden bleeding or infarction within a pituitary tumor that can cause headache, visual loss, and hormonal imbalance. Most patients experience this event only once in their lifetime, but in rare cases, it may happen again, this condition is called recurrent pituitary apoplexy. In this study, we analyzed nearly 300 patients from the Spanish Pituitary Apoplexy Registry, one of the largest series worldwide. Only 3% of patients had a second episode, and these recurrences were generally not more severe than the first. Recurrence was slightly more common in patients with larger or invasive tumors and in those previously treated with dopamine agonists, such as cabergoline. Overall, the study shows that recurrent pituitary apoplexy is very uncommon and that patients can be reassured about their favorable long-term prognosis. Continued follow-up is recommended, especially for those with residual or invasive tumors, but no specific additional monitoring is usually required.
Publisher
SAGE Publications,SAGE Publishing
Subject
